A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Trial Details

NCT ID

NCT07562022

Phase

PHASE3

Sponsor

Sinocelltech Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• SCTB35 injection
• Rituximab
• Lenalidomide

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Age 18-80 years old
• Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
• Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination wi…
• Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.